Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Requip, Requip Xl. Every FDA application for this active ingredient: 2 branded and 21 generic.
As of Nov 15, 2026, FDA lists 23 applications for Ropinirole Hydrochloride (sold as Requip, Requip Xl), first approved Sep 19, 1997, with 2 new uses approved and 0 published complete response letters.
First approved: Sep 19, 1997
Applications: 23
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $66.2M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Haruropi, new approvalDrugs with a new route of administration indicated for the treatment of Parkinson's disease. · Hisamitsu Pharmaceutical Co., Inc. · Sep 20, 2019
Requip CR, new approvalDrugs in new dosage forms and with a new dosage. · GlaxoSmithKline K.K. · Jun 29, 2012
Clinical Trials
2 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Glaxosmithkline LLC
Hikma
Zydus Lifesciences
Alembic Ltd
Aurobindo Pharma USA
Accord Hlthcare